IP Library Granted Patent US 10,953,102
Granted Patent B2
US 10,953,102 · App. 16/722,691 · Granted Mar 23, 2021

Compositions and methods for increasing efficiency of cardiac metabolism

Inventor: Andrew D. Levin (Newton, MA)
Assignee: IMBRIA PHARMACEUTICALS, INC.
A61K47/551A61K31/495A61K47/55A61K47/60C07D401/12A61P3/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,953,102
App. No.
16/722,691
Granted
Mar 23, 2021
Kind
B2
Abstract

Compositions and methods for increasing efficiency of cardiac metabolism are provided.

Claims (7)

1. A method of increasing cardiac efficiency in a subject, the method comprising providing to a subject a compound represented by formula (X):

thereby increasing cardiac efficiency in the subject.

2. The method of claim 1 , wherein the compound is provided in a therapeutically effective amount to treat a subject having a disease, disorder, or condition that comprises impaired mitochondrial function or altered fatty acid oxidation.

3. The method of claim 2 , wherein the disease, disorder, or condition is selected from the group consisting of heart failure, ischemic heart disease, diabetic cardiomyopathy, rheumatic heart disease, valvular heart disease, aneurysm, atherosclerosis, high blood pressure, peripheral arterial disease, angina, atherosclerosis, coronary artery disease, coronary heart disease, heart attack, atherosclerosis, cerebral vascular disease, stroke, transient ischemic attacks, atherosclerosis, cardiomyopathy, pericardial disease, valvular heart disease, and congenital heart disease.

4. The method of claim 3 , wherein the disease, disorder, or condition is heart failure or angina.

5. The method of claim 1 , wherein the compound is provided orally.

6. The method of claim 5 , wherein the compound is provided in a format selected from the group consisting of a tablet, troche, lozenge, aqueous suspension, oily suspension, emulsion, hard capsule, soft capsule, and syrup.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2020
From: CARNOT, LLC
To: IMBRIA PHARMACEUTICALS, INC.
Reel/Frame 051687/0226 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2020
From: CARNOT, LLC
To: IMBRIA PHARMACEUTICALS, INC.
Reel/Frame 051687/0246 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2020
From: RA CAPITAL MANAGEMENT, LLC
To: CARNOT, LLC
Reel/Frame 051687/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2020
From: LEVIN, ANDREW
To: RA CAPITAL MANAGEMENT, LLC
Reel/Frame 051687/0280 →
Continuity (7)
Continuation 16011196 · Jun 18, 2018
Provisional Application 62647926 · Mar 26, 2018
Provisional Application 62637434 · Mar 2, 2018
Provisional Application 62710316 · Feb 16, 2018
Provisional Application 62524237 · Jun 23, 2017
Provisional Application 62522214 · Jun 20, 2017
Related Publication 20200138962A1 · May 7, 2020
Cited By (7)
US 12,233,058 US 12,285,428 US 12,318,382 US 12,318,453 US 12,502,389 US 12,569,480 US 12,649,720